title: [Dietary therapy of epilepsy].
abstract: Reappraisal of ketogenic diets (KD) were delayed in Japan compared to USA and Korea. The reasons are unknown, but possible explanations are (1) Japanese food culture prefers rice and less fat and (2) ACTH therapy is preferred for West syndrome in Japan. Since Japanese child neurologists were surprised at dramatic effects on glucose transporter 1 deficiency syndrome (Glut-1DS) in 2003, KD have been slowly accepted for treatment of epilepsy in Japan. New generation KD including modified Atkins diet (mAD) are preferred to classical KD. KD can be causal therapy in Glut-1DS and some of mitochondrial disorders, though anti-epileptic drugs are symptomatic therapy. KD can alleviate intractable seizures in epilepsies with brain malformation in addition to West syndrome and Dravet syndrome, etc. KD may work for brain tumor, cancer, neurodegenerative disorders including Alzheimer's disease. C7-8 triglycerides or fatty acid esters are under development as medicines replacing KD.
authors.forename: Katsumi
authors.initials: K
authors.lastname: Imai
authors.forename: Eiko
authors.initials: E
authors.lastname: Ishihara
authors.forename: Hiroko
authors.initials: H
authors.lastname: Ikeda
mesh_terms: D002239:Carbohydrate Metabolism, Inborn Errors / Q000178:diet therapy; D000075202:Contraindications; D050528:Diet, Carbohydrate-Restricted; D055423:Diet, Ketogenic / Q000009:adverse effects / Q000639:trends; D004827:Epilepsy / Q000178:diet therapy*; D006801:Humans; D028361:Mitochondrial Diseases / Q000178:diet therapy; D009004:Monosaccharide Transport Proteins / Q000172:deficiency
chemical_list: D009004:Monosaccharide Transport Proteins